1-9 of 9
James P. Dean, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134431
Published: 2020
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3054.
https://doi.org/10.1182/blood-2019-123327
Published: 2019
Journal Articles

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Isabelle G. Solman, MS, Marlene Taylor, MS, Hana You, MS, Susan M. O'Brien, MD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, John C. Byrd, MD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Ann Mongan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3114.
https://doi.org/10.1182/blood-2018-99-110848
Published: 2018
Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2018-99-110847
Published: 2018
Journal Articles

Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study

Alessandra Tedeschi, MD, Carolyn Jane Owen, MD FRCPC, Tadeusz Robak, MD PhD, Paul M. Barr, MD, Osnat Bairey, MD, Peter Hillmen, MBChB, PhD, Steven Coutre, MD, Stephen Devereux, FRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Helen McCarthy, MBBS, PhD, Jianyong Li, MD, David Simpson, MBChB, Tanya Siddiqi, MD, Giri Iyer, MBA, Indu D. Lal, MD, Jeremiah Trudeau, PhD, Sandra Dai, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jan A. Burger, MD PhD, Paolo Ghia, MD PhD, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1746.
https://doi.org/10.1182/blood.V130.Suppl_1.1746.1746
Published: 2017
Journal Articles

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

Suliman Al-Fayoumi, PhD, MBA, Lixia Wang, PhD, Hanbin Li, PhD, Russ Wada, PhD, James P. Dean, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4080.
https://doi.org/10.1182/blood.V122.21.4080.4080
Published: 2013
Journal Articles

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Srdan Verstovsek, MD, PhD, James P. Dean, MD, PhD, Paul Cernohous, MS, Rami S Komrokji, MD, John F. Seymour, MBBS, FRACP, PhD, Ruben A. Mesa, MD, Mary S Campbell, MD, Susan E. Caldwell, PhD, Lixia Wang, PhD, Han Myint, MD
Journal: Blood
Blood (2013) 122 (21): 395.
https://doi.org/10.1182/blood.V122.21.395.395
Published: 2013